Kasabach-Merritt syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 13: Line 13:
  | accessdate =2006-05-15}}</ref> is directed by the presenting signs and symptoms, and can involve:
  | accessdate =2006-05-15}}</ref> is directed by the presenting signs and symptoms, and can involve:
*blood counts, clotting studies, and other laboratory testing
*blood counts, clotting studies, and other laboratory testing
*imaging tests ([[Medical ultrasonography|ultrasound]], [[CT scan]], [[MRI]], sometimes [[angiography]], and rarely [[nuclear medicine]] scans)
*[[biopsy]] of the tumor.
==Laboratory Findings==
==Laboratory Findings==
Patients uniformly show severe thrombocytopenia, low [[fibrinogen]] levels, high [[fibrin degradation products]] (due to [[fibrinolysis]]), and [[microangiopathic hemolytic anemia|microangiopathic hemolysis]].
Patients uniformly show severe thrombocytopenia, low [[fibrinogen]] levels, high [[fibrin degradation products]] (due to [[fibrinolysis]]), and [[microangiopathic hemolytic anemia|microangiopathic hemolysis]].

Latest revision as of 17:09, 21 September 2012

Kasabach-Merritt syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Kasabach-Merritt syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kasabach-Merritt syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kasabach-Merritt syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kasabach-Merritt syndrome laboratory findings

CDC on Kasabach-Merritt syndrome laboratory findings

Kasabach-Merritt syndrome laboratory findings in the news

Blogs on Kasabach-Merritt syndrome laboratory findings

Directions to Hospitals Treating Kasabach-Merritt syndrome

Risk calculators and risk factors for Kasabach-Merritt syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The diagnostic workup[1] is directed by the presenting signs and symptoms, and can involve:

Laboratory Findings

Patients uniformly show severe thrombocytopenia, low fibrinogen levels, high fibrin degradation products (due to fibrinolysis), and microangiopathic hemolysis.

References

  1. Krafchik, Bernice R (2005-12-19). "Kasabach-Merritt Syndrome". eMedicine - Hematology. WebMD. Retrieved 2006-05-15. Check date values in: |date= (help)

Template:WH Template:WS